Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
7.95
-0.92 (-10.37%)
At close: Dec 30, 2024, 4:00 PM
7.90
-0.05 (-0.63%)
After-hours: Dec 30, 2024, 6:49 PM EST
Candel Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
42
Market Cap
258.18M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 125.00K | - | - |
| Dec 31, 2021 | 125.00K | - | - |
| Dec 31, 2020 | 125.00K | - | - |
| Dec 31, 2019 | 125.00K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 393.90B |
| Johnson & Johnson | 87.70B |
| Merck & Co. | 63.17B |
| AbbVie | 55.53B |
| AstraZeneca | 51.21B |
| Novartis AG | 49.94B |
| Thermo Fisher Scientific | 42.37B |
| Abbott Laboratories | 41.22B |
CADL News
- 14 days ago - Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares - GlobeNewsWire
- 17 days ago - Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
- 18 days ago - Candel Therapeutics Announces Pricing of Public Offering - GlobeNewsWire
- 18 days ago - Candel Therapeutics Announces $80 Million Proposed Public Offering - GlobeNewsWire
- 19 days ago - Candel Therapeutics: Surprising Win Puts Potential Drug Approval In Sight - Seeking Alpha
- 19 days ago - Candel Therapeutics Stock Surges Over 100% - Here's Why - Benzinga
- 19 days ago - Candel Therapeutics' cancer drug meets late-stage trial goals - Reuters
- 19 days ago - Candel Therapeutics Announces CAN-2409 Achieved Primary Endpoint in Phase 3 Prostate Cancer Trial, Showing Significantly Improved Disease-Free Survival - GlobeNewsWire